1146 related articles for article (PubMed ID: 24766435)
21. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C; Knörr F; Brugières L; Woessmann W
Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
[TBL] [Abstract][Full Text] [Related]
24. A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma.
Wang E; Papalas J; Siddiqi I; Stoecker M; Rehder C; Sebastain S; Burchette J; Huang Q
Pathol Res Pract; 2011 Aug; 207(8):522-6. PubMed ID: 21763080
[TBL] [Abstract][Full Text] [Related]
25. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A; Soma L
Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
27. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
K Singh V; Werner S; Hackstein H; Lennerz V; Reiter A; Wölfel T; Damm-Welk C; Woessmann W
Clin Exp Immunol; 2016 Oct; 186(1):96-105. PubMed ID: 27414060
[TBL] [Abstract][Full Text] [Related]
28. The t(2;5) in human lymphomas.
Kadin ME; Morris SW
Leuk Lymphoma; 1998 Apr; 29(3-4):249-56. PubMed ID: 9684923
[TBL] [Abstract][Full Text] [Related]
29. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
Yu R; Chen G; Zhou C; Gao Z; Shi Y; Shi Y; Zhou X; Xie J; Liu H; Gong L
Leuk Res; 2012 Sep; 36(9):1141-6. PubMed ID: 22726922
[TBL] [Abstract][Full Text] [Related]
30. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
31. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
32. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
[TBL] [Abstract][Full Text] [Related]
34. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
[TBL] [Abstract][Full Text] [Related]
36. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
38. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
Ruf S; Hebart H; Hjalgrim LL; Kabickova E; Lang P; Steinbach D; Schwabe GC; Woessmann W
Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction.
Damm-Welk C; Schieferstein J; Schwalm S; Reiter A; Woessmann W
Br J Haematol; 2007 Aug; 138(4):459-66. PubMed ID: 17608768
[TBL] [Abstract][Full Text] [Related]
40. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
